PIRIDE 2 TAB is an oral antidiabetic medication formulated with Glimepiride 2 mg, intended for the treatment of patients with Type 2 Diabetes Mellitus. Glimepiride is a second-generation sulfonylurea that exerts its hypoglycemic effects by stimulating the pancreatic beta cells to release insulin in a glucose-dependent manner. PIRIDE 2 TAB is a core therapeutic agent in the management of hyperglycemia, particularly in patients where lifestyle modifications alone are insufficient, or where other oral antidiabetics are either contraindicated or require supplementation.
The 2 mg strength is an intermediate dosage designed for patients who have not achieved optimal blood glucose control on 1 mg or who require a moderately enhanced insulinotropic response. Glimepiride’s once-daily dosing, long duration of action, and minimal risk of severe hypoglycemia compared to older sulfonylureas make it an ideal agent for long-term diabetes control. It is especially useful in middle-aged and elderly patients due to its favorable cardiovascular profile and low incidence of side effects when properly dosed.
Bluepill Express ensures the manufacturing of PIRIDE 2 TAB in WHO-GMP, ISO, and DCGI-approved facilities. Every batch undergoes rigorous quality assurance protocols, including raw material analysis, in-process controls, and finished product evaluations such as assay, dissolution, and stability. This commitment to precision ensures that the final formulation offers excellent bioavailability, consistency, and therapeutic efficacy across markets.
PIRIDE 2 TAB works by closing ATP-sensitive potassium channels in pancreatic beta cells, leading to depolarization and insulin release. This mechanism is particularly effective in patients with residual beta-cell function. The drug begins to act within 30 to 60 minutes of ingestion and provides glucose-lowering effects for up to 24 hours. Patients typically consume the tablet with their first substantial meal of the day to reduce the risk of hypoglycemia and synchronize the insulin release with postprandial glucose levels.
This formulation is suitable for standalone use in early-stage diabetes or can be combined with Metformin, DPP-4 inhibitors, or insulin therapy in more advanced cases. It is often included in dual or triple therapy regimens as per individualized glycemic targets set by endocrinologists and diabetologists.
PIRIDE 2 TAB has a high safety margin but must be prescribed carefully in patients with renal or hepatic impairment. Common adverse reactions include mild hypoglycemia, dizziness, or gastrointestinal discomfort, especially during the initiation phase. However, adherence to dietary patterns and dosage instructions can minimize these risks. The product is contraindicated in patients with Type 1 Diabetes, diabetic ketoacidosis, or known sulfonylurea hypersensitivity.
With the growing global burden of diabetes, especially in low- and middle-income countries, PIRIDE 2 TAB is well-positioned for large-scale export and distribution. Bluepill Express offers comprehensive third-party manufacturing services for this product, including product registration support, customized branding, multilingual packaging, and documentation aligned with pharmacopeial standards like IP, BP, or USP.
Description provided by bluepill express.
FIEO Registered
Export Ready
